X0N11

X0N11 is a preclinical-stage glyco-humanized polyclonal antibody (GH-pAb) being developed by Xenothera for the treatment of solid tumors. As part of Xenothera's oncology pipeline, X0N11 utilizes the company's proprietary platform to produce antibodies that are human-like in their glycosylation patterns, which is intended to reduce immunogenicity and the risk of serum sickness compared to traditional animal-derived polyclonal antibodies. The drug is designed to provide a multi-epitopic approach, potentially targeting several antigens or epitopes on tumor cells simultaneously to enhance therapeutic efficacy and overcome tumor heterogeneity or resistance mechanisms.